Revance Therapeutics, Inc. (NASDAQ:RVNC) will hold its 3Q20 earnings conference call with the financial community on 9th November 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.revance.com
Earnings Expectation
Revance Therapeutics, Inc. is expected to report third quarter earnings results, after market close, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.03 per share from revenue of $ 1.78 million. Looking ahead, the full year loss are expected at $ 4.31 per share on the revenues of $ 8.19 million.
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The companys lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX.
